| DCC3864 |
o-1918 |
Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly. |
|
| DCC3865 |
Oa-adp-hpd |
Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor |
|
| DCC3866 |
Oat-1441 |
Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase) |
|
| DCC3867 |
O-bn-thaz Fumarate |
Potent agonist of the human 5-HT2A and 5-HT2C receptors |
|
| DCC3868 |
Obtusaquinone
Featured
|
Obtusaquinone (OBT) is a potent antineoplastic agent with significant therapeutic potential, particularly in aggressive cancers such as glioblastoma and breast cancer. Its mechanism of action involves the induction of oxidative stress and endoplasmic reticulum (ER) stress, leading to cancer cell death. OBT has demonstrated promising in vivo activity, including the ability to penetrate the blood-brain barrier (BBB) and target brain tumors, making it a particularly valuable candidate for treating central nervous system (CNS) malignancies. |
|
| DCC3869 |
Obtusilactone A |
Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints |
|
| DCC3870 |
Obtusilactone B
Featured
|
Specific inhibitor of vaccinia-related kinase 1 (VRK1)-mediated phosphorylation of barrier-to-autointegration factor (BAF) |
|
| DCC3871 |
O-carbamate 66 |
Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97% |
|
| DCC3872 |
Ocean Blue Se |
Blue fluorescent labeling reagent |
|
| DCC3873 |
Octamoxin |
Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI) |
|
| DCC3874 |
Octimibate |
Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor |
|
| DCC3875 |
Octreotideacetate GMP grade
Featured
|
Agonist of sst2, sst3 and sst5 somatostatin receptors |
|
| DCC3876 |
Ofh243 |
Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist |
|
| DCC3877 |
Ofh244 |
Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist |
|
| DCC3878 |
Ofh3911 |
Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist |
|
| DCC3879 |
Ofh3912 |
Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist |
|
| DCC3880 |
Og488-bapta-1-am |
Cell-permeable, fluorescent Ca2+ indicator |
|
| DCC3881 |
Oga-in-5i |
Novel potent O-GlcNAcase (OGA) inhibitor (IC 50 : 46 nM), increasing the level of O-GlcNAcylated protein in cells and displaying suitable pharmacokinetic properties and brain permeability |
|
| DCC3882 |
Ohinitib |
Novel HSF1 inhibitor for target-based cancer therapy |
|
| DCC3883 |
Oh-nplh2 |
Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo |
|
| DCC3884 |
Oicr766a |
Novel Bax activator, having greatest effect enhancing the pro-apoptotic activity of Bax with EC50 values of ∼0.1 μM and ∼0.9 μM, respectively, inducing cell death by a Bax/Bak-dependent mechanism |
|
| DCC3885 |
Ojak-989 |
Novel orally bioavailable potent JAK-1 inhibitor |
|
| DCC3886 |
Okadaic Acid |
Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3887 |
Okadaic Acid Potassium Salt |
Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3888 |
Okadaic Acid Sodium Salt |
Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor |
|
| DCC3889 |
Olanzapine Pamoate |
Dopamine antagonist as an atypical antipsychotic |
|
| DCC3890 |
Olanzapine/samidorphan |
Combination of the atypical antipsychotic olanzapine and opioid receptor antagonist samidorphan for treatment of adults with schizophrenia or bipolar I disorder |
|
| DCC3891 |
Oleanonic Acid |
Natural inhibitor of the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site, reducing the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes, ameliorating pressure overload-induced cardiac hypertrophy |
|
| DCC3892 |
Oleracein E |
Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt |
|
| DCC3893 |
Olfr895-agonist-10 |
Novel specific agonist of odorant receptor 895 (Olfr895) |
|
